litlas
Log inCreate account

Franco M. Muggia

Active 1968–2020

Also published as
FRANCO M. MUGGIA
89
Papers
20,202
Citations
78
h-index
89
i10-index

Citations

Citations per year for Franco M. Muggia1970: 1 citations1972: 1 citations1973: 2 citations1974: 4 citations1975: 3 citations1976: 6 citations1977: 10 citations1978: 7 citations1979: 18 citations1980: 27 citations1981: 30 citations1982: 38 citations1983: 38 citations1984: 36 citations1985: 44 citations1986: 26 citations1987: 28 citations1988: 27 citations1989: 25 citations1990: 26 citations1991: 42 citations1992: 33 citations1993: 46 citations1994: 36 citations1995: 46 citations1996: 75 citations1997: 85 citations1998: 72 citations1999: 104 citations2000: 92 citations2001: 122 citations2002: 97 citations2003: 108 citations2004: 166 citations2005: 146 citations2006: 122 citations2007: 127 citations2008: 138 citations2009: 134 citations2010: 138 citations2011: 171 citations2012: 151 citations2013: 145 citations2014: 157 citations2015: 144 citations2016: 140 citations2017: 113 citations2018: 77 citations2019: 319 citations2020: 309 citations2021: 290 citations2022: 245 citations2023: 122 citations2024: 183 citations2025: 93 citations2026: 2 citations1971: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,976 citing papers, 32.8% of this breakdownUnited Kingdom: 386 citing papers, 6.4% of this breakdownChina: 368 citing papers, 6.1% of this breakdownItaly: 313 citing papers, 5.2% of this breakdownCanada: 242 citing papers, 4% of this breakdownGermany: 235 citing papers, 3.9% of this breakdownFrance: 231 citing papers, 3.8% of this breakdownJapan: 228 citing papers, 3.8% of this breakdownNetherlands: 190 citing papers, 3.1% of this breakdownSpain: 147 citing papers, 2.4% of this breakdownAustralia: 145 citing papers, 2.4% of this breakdownIndia: 137 citing papers, 2.3% of this breakdown
0%32.8%Other 23.8%

Institutions

Fields

  • Medicine62.2%
  • Biochemistry, Genetics and Molecular Biology16.9%
  • Materials Science11.2%
  • Immunology and Microbiology4.4%
  • Engineering1.4%
  • Pharmacology, Toxicology and Pharmaceutics1.3%
  • Other2.6%

Topics

  • Chemotherapy-induced cardiotoxicity and mitigation5.2%
  • Nanoparticle-Based Drug Delivery5.1%
  • Cancer Treatment and Pharmacology4.4%
  • Ovarian cancer diagnosis and treatment4.2%
  • RNA Interference and Gene Delivery2.7%
  • PARP inhibition in cancer therapy2%
  • Other76.4%

Coauthors

All papers

Open in search
  1. Risk Factors for Doxorubicin-lnduced Congestive Heart Failure

    Authors: Daniel D. Von Hoff, MAXWELL W. LAYARD, PETER BASA, HUGH L. DAVIS, ANN L. VON HOFF, MARCEL ROZENCWEIG, FRANCO M. MUGGIA - Annals of Internal Medicine 1979 cited by 2,431

  2. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions

    Authors: Asher Chanan‐Khan, János Szebeni, Sándor Sávay, Leonard Liebes, NAILA RAFIQUE, Carl R. Alving, Franco M. Muggia - Annals of Oncology 2003 cited by 469

  3. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention

    Authors: János Szebeni, Franco M. Muggia, Alberto Gabizón, Yechezkel Barenholz - Advanced Drug Delivery Reviews 2011 cited by 413

  4. Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2

    Authors: Tamar Safra, Franco M. Muggia, Susan Jeffers, Denice Tsao‐Wei, Susan Groshen, Olga Lyass, Randal H. Henderson, Gerald J. Berry, Alberto Gabizón - Annals of Oncology 2000 cited by 613

  5. Kaposis sarcoma and Pneumocystis pneumonia among homosexual men-New York City and California.

    Authors: Alvin E. Friedman‐Kien, L Laubenstein, Michael Marmor, Kenneth B. Hymes, J Green, A Ragaz, J Gottleib, Franco M. Muggia, Rita I. Demopoulos, Miranda Ritterman Weintraub - MMWR Morbidity and Mortality Weekly Report 1981 cited by 1,045

  6. Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery

    Authors: Franco M. Muggia, Andrea Bonetti, James D. Hoeschele, Marcel Rozencweig, Stephen B. Howell - Journal of Clinical Oncology 2015 cited by 175

  7. Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

    Authors: William E. Winter, G. Larry Maxwell, Chunqiao Tian, Jay W. Carlson, Robert F. Ozols, Peter G. Rose, Maurie Markman, Deborah K. Armstrong, Franco M. Muggia, William P. McGuire - Journal of Clinical Oncology 2007 cited by 846

  8. Complement Activation by Cremophor EL as a Possible Contributor to Hypersensitivity to Paclitaxel: an In Vitro Study

    Authors: János Szebeni, Carl R. Alving, Franco M. Muggia - JNCI Journal of the National Cancer Institute 1998 cited by 344

  9. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience

    Authors: Kate Oliver, William E. Brady, Michael J. Birrer, David M. Gershenson, Gini F. Fleming, Larry J. Copeland, Krishnansu S. Tewari, Peter A. Argenta, Robert S. Mannel, Angeles Alvarez Secord, Jean-Marie Stephan, David G. Mutch, Frederick B. Stehman, Franco M. Muggia, Peter G. Rose, Deborah K. Armstrong, Michael A. Bookman, Robert A. Burger, John Farley - Gynecologic Oncology 2017 cited by 99

  10. Camptothecins: a review of their development and schedules of administration

    Authors: John O’Leary, Franco M. Muggia - European Journal of Cancer 1998 cited by 217

  11. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

    Authors: Beatrice Uziely, Susan Jeffers, Rut Isacson, K Kutsch, Denice D. Wei‐Tsao, Zohar Yehoshua, E Libson, Franco M. Muggia, Alberto Gabizón - Journal of Clinical Oncology 1995 cited by 478

  12. Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

    Authors: William E. Winter, G. Larry Maxwell, Chunqiao Tian, Michael J. Sundborg, G. Scott Rose, Peter G. Rose, Stephen C. Rubin, Franco M. Muggia, William P. McGuire - Journal of Clinical Oncology 2007 cited by 403

  13. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.

    Authors: Sandra Demaria, M Volm, Richard L. Shapiro, Herman Yee, Ruth Oratz, Silvia C. Formenti, Franco M. Muggia, W. Fraser Symmans - 2001 cited by 304

  14. ROLE OF COMPLEMENT ACTIVATION IN HYPERSENSITIVITY REACTIONS TO DOXIL AND HYNIC PEG LIPOSOMES: EXPERIMENTAL AND CLINICAL STUDIES

    Authors: János Szebeni, Lajos Baranyi, Sándor Sávay, János Milosevits, Rolf Bünger, Peter Laverman, Josbert M. Metselaar, G. Storm, Asher Chanan‐Khan, Leonard Liebes, Franco M. Muggia, Rivka Cohen, Yechezkel Barenholz, Carl R. Alving - Journal of Liposome Research 2002 cited by 209

  15. PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues

    Authors: Pooja Murthy, Franco M. Muggia - Cancer Drug Resistance 2019 cited by 49

  16. Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

    Authors: Bradley J. Monk, Thomas J. Herzog, Stanley B. Kaye, Carolyn Krasner, Jan B. Vermorken, Franco M. Muggia, Éric Pujade-Lauraine, Alla Lisyanskaya, А. Н. Махсон, Janusz Rolski, Vera Gorbounova, Prafull Ghatage, Mariusz Bidziński, Keng Shen, Hys Ngan, Ignace Vergote, Joo‐Hyun Nam, Youn Choi Park, Claudia Lebedinsky, Andrés Poveda - Journal of Clinical Oncology 2010 cited by 404

  17. Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer.

    Authors: Nagashree Seetharamu, E. Kim, Howard S. Höchster, Francisco J. Plaza Martín, Franco M. Muggia - 2010 cited by 107

  18. Daunomycin-induced cardiotoxicity in children and adults

    Authors: Daniel D. Von Hoff, Marcel Rozencweig, Maxwell W. Layard, Milan Slavik, Franco M. Muggia - The American Journal of Medicine 1977 cited by 435

  19. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.

    Authors: Yi He Ling, Leonard Liebes, Jian Jiang, James F. Holland, Peter J. Elliott, Julian Adams, Franco M. Muggia, Román Pérez-Soler - 2003 cited by 262

  20. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis

    Authors: Bradley J. Monk, Thomas J. Herzog, Stanley B. Kaye, Carolyn Krasner, Jan B. Vermorken, Franco M. Muggia, Éric Pujade-Lauraine, Youn C. Park, Trilok Parekh, Andrés Poveda - European Journal of Cancer 2012 cited by 94

  21. Cis-diamminedichloroplatinum (II)

    Authors: Marcel Rozencweig, DANIEL D. VON HOFF, MILAN SLAVIK, FRANCO M. MUGGIA - Annals of Internal Medicine 1977 cited by 436

  22. Immediate Adjuvant Chemotherapy versus Observation with Treatment at Relapse in Pathological Stage II Testicular Cancer

    Authors: Stephen D. Williams, Donald M. Stablein, Lawrence H. Einhorn, Franco M. Muggia, R B Weiss, John P. Donohue, David F. Paulson, Kurt Brunner, Edwin M. Jacobs, Joseph T. Spaulding, William D. DeWys, E. David Crawford - New England Journal of Medicine 1987 cited by 391

  23. Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma

    Authors: Stephen J. Schuster, Sattva S. Neelapu, Barry L. Gause, John E. Janik, Franco M. Muggia, Jon P. Gockerman, Jane N. Winter, Christopher R. Flowers, Daniel A. Nikcevich, Eduardo M. Sotomayor, Dean McGaughey, Elaine S. Jaffe, Elise A. Chong, Craig W. Reynolds, Donald A. Berry, Carlos Ferreira Santos, Mihaela A. Popa, Amy M. McCord, Larry W. Kwak - Journal of Clinical Oncology 2011 cited by 243

  24. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.

    Authors: Parkash S. Gill, Byron M. Espina, Franco M. Muggia, S Cabriales, Anil Tulpule, Joan A. Esplin, Howard A. Liebman, Eric A. Forssen, Michael E. Ross, A Levine - Journal of Clinical Oncology 1995 cited by 242